RESULTS: Pulmonary fungal infection was confirmed in (77.8%) out of COPD patients with comorbidities versus (53.1%) in COPD patients without comorbidities (53.1%) (P< 0.001) with predominance of candida and aspergillus spp., in both groups. Serum GM was positive in 16 (19.7%) COPD patients with comorbidities versus 7 (7 .3%) in COPD patients without comorbidities (P=0.02). BAL GM had a higher diagnostic yield in comparison to serum GM and 1,3BDG. There was no significant association between culture-positivity and radiological findings. Mechanical ventilation, corticosteroid therapy, ICU admission and age were the major risk factors for pulmonary fungal infection in COPD patients with comorbiditi es (P = 0.012; ODR=2.23, P = 0.028; ODR=1.99, P = 0.025; ODR=1.94, P = 0.034; respectively).COPD patients with comorbidities had significantly higher mortality rate (12.3%) than COPD patients without comorbidities (3.1%) (P=0.01).